Ernexa Therapeutics Inc (ERNA) - News Archive

Showing 3 of 3 results.

Ernexa Therapeutics Reinvents Itself: New Funding and Strategic Focus Set Stage for Breakthroughs in Ovarian Cancer Amid Industry Turbulence,

In a significant strategic maneuver, Ernexa Therapeutics has successfully concluded a new funding round aimed at bolstering its endeavors in the realm of ovarian cancer treatment. This critical injection of capital arri...

Apr 3, 2025 • Major Pharmaceutical Preparations Industry Shares #cell therapy

Eterna Therapeutics Faces Challenges Amid Leadership Changes and Financial Losses: Can New Vision Propel mRNA Innovation

CAMBRIDGE, Mass.—In a bold move, Eterna Therapeutics Inc. recently announced the appointment of Dr. Elena Ratner, a world-renowned expert in obstetrics and gynecology from Yale University, to its Board of Directors. The...

Jan 9, 2025 • Major Pharmaceutical Preparations Industry Management Changes #ovarian cancer

Eterna Therapeutics Secures $9.2 Million Convertible Debt and Warrant Financing to Propel mRNA Cell Engineering Capabilities.

Eterna Therapeutics: Secures $9.2 Million Funding for Advancing mRNA Cell EngineeringCAMBRIDGE, Mass., Dec. 14, 2023 - Eterna Therapeutics Inc. (Nasdaq: ERNA), a leading life science company focused on harnessing the po...

Dec 14, 2023 • Major Pharmaceutical Preparations Industry Financing Agreement